Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-05-24
DOI
10.3389/fphar.2016.00131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
- (2016) Jifang Gong et al. BMC CANCER
- Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
- (2015) G. Gebhart et al. ANNALS OF ONCOLOGY
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
- (2015) N. Pandit-Taskar et al. CLINICAL CANCER RESEARCH
- Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
- (2015) Marc Peeters et al. DRUGS
- Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
- (2015) Kristoff Muylle et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
- (2015) Marika Ciprotti et al. JOURNAL OF CLINICAL ONCOLOGY
- TGF- Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
- (2015) M. W. den Hollander et al. JOURNAL OF NUCLEAR MEDICINE
- Antibodies to watch in 2016
- (2015) Janice M. Reichert mAbs
- Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
- (2015) Eva J. ter Weele et al. Oncotarget
- 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
- (2015) Patrizia Mondello et al. Oncotarget
- 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
- (2015) Catherina Willemien Menke-van der Houven et al. Oncotarget
- 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
- (2014) Neeta Pandit-Taskar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
- (2014) S. F. Oosting et al. JOURNAL OF NUCLEAR MEDICINE
- Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
- (2014) S. J. van Asselt et al. JOURNAL OF NUCLEAR MEDICINE
- Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
- (2014) Nerissa Therese Viola-Villegas et al. MOLECULAR PHARMACEUTICS
- Next-generation antibodies
- (2014) James B. Evans et al. NATURE REVIEWS DRUG DISCOVERY
- Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer
- (2014) Idris Bahce et al. EJNMMI Research
- 89Zr-Bevacizumab PET Imaging in Primary Breast Cancer
- (2013) S. B. M. Gaykema et al. JOURNAL OF NUCLEAR MEDICINE
- Multicenter Harmonization of 89Zr PET/CT Performance
- (2013) N. E. Makris et al. JOURNAL OF NUCLEAR MEDICINE
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET
- (2012) Saiyada N. F. Rizvi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- (2012) Linda Sofie Lindström et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
- (2011) Chantal Tsé et al. CANCER TREATMENT REVIEWS
- VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients
- (2011) Wouter B. Nagengast et al. EUROPEAN JOURNAL OF CANCER
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
- (2010) E C Dijkers et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2–Positive Tumor Load
- (2010) Thijs H. Oude Munnink et al. JOURNAL OF CLINICAL ONCOLOGY
- Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010
- (2010) Michel Meignan et al. LEUKEMIA & LYMPHOMA
- Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
- (2010) Maria J W D Vosjan et al. Nature Protocols
- p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
- (2009) Lars R. Perk et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients
- (2009) P. K.E. Borjesson et al. JOURNAL OF NUCLEAR MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More